Jump to content
Powered by

uniQure acquires HAE Accelerator Winner InoCard GmbH

Heidelberg start-up develops gene therapy for the treatment of cardiac insufficiency. UniQure N.V. pays 3 million euros in cash and shares for the acquisition; additional milestone payments and future revenue shares were agreed upon. The physicians Prof. Dr. Hugo Katus, medical director of the Heidelberg Clinic for Cardiology, Angiology and Pneumology, and Prof. Dr. Patrick Most, head of the Institute for Molecular and Translational Cardiology at the University Clinic Heidelberg, may take the credit for this success. For many years they have carried out research and fought for their idea of treating myocardial insufficiency with the help of a gene therapy. In a study with pigs that suffered from cardiac insufficiency the 12-month survival rate was 90% following a treatment with the gene therapy AAV-S100A1.

Most, who will now be the managing director for uniQure, represented InoCard successfully in 2013 in the Business Plan Competition HAE Accelerator. The start-up prevailed against eight other life-science start-ups from Germany, Austria and Great Britain to win the Investors’ Choice Award. In addition to the publicity, the start-up also benefited from the accompanying coaching: “The cooperation with the BioRN Cluster Management gave us a whole new boost,” declared Most.

Christian Tidona, managing director of the BioRN Network e.V. and the BioRN Cluster Management GmbH, had coached all participating start-ups intensively during the HAE Summer Camp. With reference to the success now achieved by one of these start-ups, he said: “I am delighted that InoCard will become part of uniQure and can now further implement its business concept. We are proud to have been able to contribute to this as a Cluster Management Organization. It also makes clear how important it is to provide scientists who wish to start a business with professional support in developing a business plan.”

Heidelberg’s Mayor Dr. Eckart Würzner sees in addition a positive signal for the science center: “InoCard is continuing its successful series: Following the victory in the ‘Health Axis Europe-Accelerator Competition’ last year, Prof. Dr. Patrick Most has managed to take an important step with his start-up. This is a decisive precondition for creating a successful enterprise from the innovative founding idea. This is also a great signal for Heidelberg as a science location. With the development of a new type of gene therapy for the treatment of chronic myocardial insufficiency InoCard makes a major contribution to society. I warmly congratulate the team and wish them much continued success in the future.”

The integration of InoCard into uniQure will be managed by Dr. Claudia Ulbrich who will then act as Executive Advisor Business Development of uniQure.

The development and first implementation of the Business Plan Competition HAE Accelerator was supported by the Federal Ministry of Education and Research (BMBF) as part of a BioRN Leading-Cluster project.

More information:
BioRN Network e.V.
Eva-Maria Gottmann
Im Neuenheimer Feld 582
69120 Heidelberg, Germany
Telephone: +49 6221 649220
E-Mail: eg(at)biorn.org

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/uniqure-acquires-hae-accelerator-winner-inocard-gmbh